REPORT HIGHLIGHT
Irritable Bowel Syndrome (IBS) treatment market was valued at USD XX billion by 2019, growing with XX% CAGR during the forecast period, 2020-2026
Market Dynamics
Irritable bowel syndrome (IBS) is an illness of gastrointestinal tract (GT) with symptoms such as severe abdominal pain and alteration of bowel habits. Generally, the movement of food is because of the intestinal contraction and the digested food is passed through the GT. The irritable bowel syndrome hampers natural movements of that muscle, by which the food material is not able to pass through the digestive tract and ultimately results in severe abdominal pain, cramping, diarrhoea, constipation, mucus in the stool, and bloating & gas. The Centers for Disease Control (CDC) and Prevention in 2015 had reported that around 3 million people in the U.S. were testified being treated with irritable bowel syndrome. This syndrome can be treated by proper medication, making favourable changes in the daily diet, and by reducing stress.
Growing prevalence of gastrointestinal diseases, increasing adoption of a sedentary lifestyle, and consumption of unhealthy diet are the major factors driving the growth of global irritable bowel syndrome treatment market. In addition, rising geriatric population and increased level of stress among individuals are other factors propelling the market growth.
Irritable bowel syndrome is considered as one of the most common gastrointestinal functional disorders, which has an estimated global incidence rate of 10-15%. Of all the patient visits to gastroenterologists, approx. 25-45% are due to symptoms of irritable bowel syndrome. Yet many people remain undiagnosed and unaware that their symptoms show a disorder that is medically recognized. Thus, the increase in awareness programs for the treatment of IBS, and launches of numerous developed pipeline drugs for the treatment are likely to create massive growth opportunities in the market. However, high competition amongst major industry players and lack of specific treatment are expected to restrict the market growth in the coming future.
Types Takeaway
Based on type, the diarrhoea-predominant (IBS-D) segment subjugated the IBS treatment market in 2018 owing to rising prevalence of gastrointestinal disorders and diseases such as increased stress levels, abdominal pain, and alteration of bowel habit. The constipation-predominant (IBS-C) segment is expected to grow at the fastest rate during the forecast period owing to the presence of promising products such as Tenapanor and SYN-010.
Linaclotide or linzess/constella is hugely adopted product in the major regions of the U.S., Germany, U.K., Japan, Italy, and Spain. In 2018, the lizness product experienced a substantial growth rate in Japan. Because of these factors, the lizness/constella product segment is estimated to dominate the market in terms of revenue by the end of 2030. Linaclotide is marketed by Allergan and Ironwood in the U.S. as Linzess. And Allergan markets the linaclotide in Europe under the brand name Constella. In China and Japan, AstraZeneca and Astellas have the exclusive rights to market and develop linaclotide as Linzess respectively.
Regional Takeaway
Presently, the North America region is predicted to continue its trend in the irritable bowel syndrome treatment market. This region is projected to register the majority of shares owing to the huge availability of medical professionals, the presence of major market players, well-established healthcare infrastructure, and rising gastrointestinal diseases. On the other hand, Asia-Pacific is estimated to be the second-largest market followed by Europe and LAMEA. High population base, rising awareness of patients, and an increase in geriatric population will boost the growth of Asia Pacific IBS treatment market.
Key Vendors Takeaway
The major players functioning in the global market are applying several strategies such as mergers & acquisitions and product launches to increase their market share. Some of the prominent players include:
• Ironwood Pharmaceuticals, Inc.
• Astellas Pharma, Inc.
• Allergan
• Takeda Pharmaceutical Company Limited
• Sebela Pharmaceuticals Inc.
• AstraZeneca
• Synergy Pharmaceuticals Inc.
• Synthetic Biologics, Inc.
• Bausch Health
• Ardelyx
The market size and forecast for each segment and sub-segments has been considered as below:
• Historical Year – 2015 to 2018
• Base Year – 2019
• Estimated Year – 2020
• Projected Year – 2026
TARGET AUDIENCE
? Traders, Distributors, and Suppliers
? Manufacturers
? Government and Regional Agencies
? Research Organizations
? Consultants
? Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL IRRITABLE BOWEL SYNDROME (IBS) TREATMENT MARKET, BY TYPES
? IBS-D
o Viberzi
o Xifaxan
o Others
? IBS-C
o Amitiza
o Linzess/Constella
o Others
GLOBAL IRRITABLE BOWEL SYNDROME (IBS) TREATMENT MARKET, BY PRODUCT
? Viberzi
? Linzess/Constella
? Xifaxan
? Amitiza
? Others
GLOBAL IRRITABLE BOWEL SYNDROME (IBS) TREATMENT MARKET, BY REGION
? North America
o The U.S.
o Canada
? Europe
o Germany
o France
o Italy
o Spain
o United Kingdom
o Rest of Europe
? Asia Pacific
o India
o China
o South Korea
o Japan
o Singapore
o Rest of APAC
? Latin America
o Brazil
o Mexico
o Argentina
o Rest of LATAM
? Middle East and Africa
o Saudi Arabia
o United Arab Emirates
o Rest of MEA